Invista 100mg Tablet contains Dasatinib, a targeted cancer medication used in the treatment of certain types of blood cancers, including Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) that are Philadelphia chromosome-positive.
| Composition | Dasatinib |
| Manufacturer | Dr Reddy’s Laboratories Ltd |
| Packing | 30 Tablets |
| Prescribed For | Chronic Myeloid Leukemia |
| Expiry | December 2027 |
Leu Kinib 70mg contains Dasatinib, a targeted therapy used for treating certain types of blood cancers such as Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Sayre Therapeutics Pvt Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Nextki 100mg Tablet contains Dasatinib, a targeted cancer therapy used to treat certain blood cancers, specifically Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Packing | 30 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Spnib 50mg/100mg contains dasatinib, a tyrosine kinase inhibitor used to treat certain types of blood cancers, specifically chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+).
| Composition | Dasatinib |
| Manufacturer | Zydus Cadila |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Sprycel 50mg contains Dasatinib, a targeted cancer therapy used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | BMS India Pvt Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dyronib 50 mg Tablet is an oral anti-cancer medication containing Dasatinib, a tyrosine kinase inhibitor used in the treatment of Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Daslemia 70 mg is an oral prescription medication that contains dasatinib, a targeted therapy classified as a tyrosine kinase inhibitor (TKI), and it is primarily used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Ph+ acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasatrue 70 mg tablet contains dasatinib and is used to treat certain types of blood cancer, especially chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It helps stop the growth of abnormal white blood cells.
| Composition | Dasatinib |
| Manufacturer | Cipla Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasashil 70mg is a prescription cancer medicine that contains Dasatinib, a tyrosine kinase inhibitor (TKI), and it is primarily used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Shilpa Medicare Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasapan 70mg is a prescription medicine that contains Dasatinib, a potent tyrosine kinase inhibitor (TKI) used in the treatment of specific blood cancers. It is primarily prescribed to patients with Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Mankind Pharma Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasamyl 100 mg contains dasatinib, and it is a targeted therapy medication used in the treatment of certain types of blood cancer, specifically Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Packing | 30 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
| Composition | Dasatinib |
| Manufacturer | AMPS Biotech Pvt Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
| Composition | Dasatinib |
| Manufacturer | Aprazer Healthcare Pvt ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
